Triple negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer characterized by the absence of expression of human epidermal growth factor receptor-2 and endocrine receptors for estrogen and progesterone, all of which are molecular targets of therapeutic agents. Patients with TNBC typically have a relatively poorer outcome compared with those with other breast cancer subtypes. This is due to an inherently aggressive clinical behavior and also to the heterogeneity of the disease, which has not enabled the development of drugs to target this subset of breast cancer.

This collection comprises a selection of recent high-quality full-text articles from Springer Nature and other prominent publishers that discuss the current understanding of TNBC and the studies being undertaken to target this heterogeneous and complex disease.